MHRA Drug Safety Update: Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride
Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse. There have been reports of worsening nasal congestion (rebound congestion) when the effects of nasal decongestant sprays or drops containing xylometazoline hydrochloride and oxymetazoline hydrochloride, referred to hereafter as ‘xylometazoline’ and ‘oxymetazoline’, wear [...]
The post MHRA Drug Safety Update: Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride appeared first on Community Pharmacy England.
Important: This alert is aggregated automatically for information only.
Always refer to the original source and follow your practice's own clinical governance procedures.
Get the weekly digest — all new alerts summarised and delivered to your NHS inbox every Monday.
View this week's digest